Open AccessEfficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial
Author(s) -
Ruijuan Dong,
Li Jiang,
Ting Yang,
Changsong Wang,
Yi Zhang,
Xu Chen,
Jianfeng Xie,
Yukun Guo,
Li Weng,
Yan Kang,
Kaijiang Yu,
Haibo Qiu,
Bin Du,
AUTHOR_ID
Publication year - 2022
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02045-21
Subject(s) - medicine , adverse effect , randomized controlled trial , odds ratio , randomization , confidence interval , clinical trial , clinical endpoint
Recombinant human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibody JS016 showed neutralizing and therapeutic effects in preclinical studies. The clinical efficacy and safety of the therapy needed to be evaluated.